Income Statement
GAIN THERAPEUTICS, INC.
GANX
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | 0.00 | 0.06 | 0.14 | 0.17 |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
- | - | 0.06 | 0.14 | 0.17 |
|
Operating Expenses
|
18.71 | 20.35 | 22.31 | 17.92 | 13.99 |
|
Research & Development
|
10.21 | 10.79 | 11.52 | 8.38 | 7.16 |
|
Selling, General & Administrative
|
8.50 | 9.56 | 10.79 | 9.54 | 6.83 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-18.71 | -20.35 | -22.25 | -17.78 | -13.82 |
|
Non-Operating Income
|
0.59 | -0.48 | -0.06 | -0.28 | 0.06 |
|
Interest Income
|
- | - | - | - | - |
|
Interest Expense
|
- | - | - | - | 0.00 |
|
Other Non-Op Income / Expense
|
- | - | - | - | - |
|
Income Before Tax
|
-19.30 | -19.87 | -22.19 | -17.50 | -13.89 |
|
Income Tax Expense
|
0.86 | 0.54 | 0.08 | 0.09 | 0.00 |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-20.16 | -20.41 | -22.27 | -17.59 | -13.89 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-18.62 | -20.27 | -22.17 | -17.71 | -13.82 |
|
Earnings Per Share (Basic)
|
-0.61 | -0.89 | -1.71 | -1.48 | -1.37 |
|
Diluted EPS
|
-0.61 | -0.89 | -1.71 | -1.48 | -1.37 |
|
Weighted Average Shares
|
32.97 | 22.88 | 13.01 | 11.88 | 10.17 |
|
Diluted Weighted Avg Shares
|
32.97 | 22.88 | 13.01 | 11.88 | 10.17 |
|
Comprehensive Income
|
-19.14 | -20.91 | -22.06 | -17.46 | -13.83 |